Exact Mass: 378.1937
Exact Mass Matches: 378.1937
Found 106 metabolites which its exact mass value is equals to given mass value 378.1937,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Isoflupredone
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
Fluprednisolone
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D005938 - Glucocorticoids C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D000893 - Anti-Inflammatory Agents Same as: D04227
Descinolone
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
Pentosidine
Pentosidine is a carbohydrate-derived advanced glycation end products (AGEs) that is considerably elevated in uremic patients. It has been identified as a uremic toxin according to the European Uremic Toxin Working Group (PMID: 22626821). Derived from ribose, a pentose, pentosidine forms fluorescent cross-links between the arginine and lysine residues in collagen. It is formed in a reaction of the amino acids with the Maillard reaction products of ribose. Although it is present only in trace concentrations among tissue proteins, it is useful for assessing cumulative damage to proteins-advanced glycation endproductsThis compound per se has no biological activities but is highly correlated to the levels of precursors of carbonyl compounds, and for this reason is considered a reliable surrogate marker for AGEs. The modification of proteins in uremia is not limited to AGEs, since advanced lipoxidation end products are also demonstrable in plasma proteins in uremia. The accumulation of these compounds does not seem to be dependent only on the decline of renal function. Carbonyl precursors of AGEs and advanced lipoxidation end products are markedly elevated in uremic patients. Preliminary cross-sectional studies in haemodialysis patients seem to indicate that the AGEs and carbonyl stress may be involved in the pathogenesis of alterations in left ventricular geometry and function in these patients. (PMID 11051031). The plasma pentosidine level in diabetic nephropathy was found to be determined by factors such as renal function control of glucose and the patients age; of these, renal function was the most critical factor. The pathological role of AGEs in diabetic nephropathy, is in the expanded mesangial area of diffuse diabetic glomerulosclerosis, with nodular lesions, characteristic of diabetic nephropathy. These suggests a potential link of AGEs accumulation, which may be determined by renal function, control of glucose and age, to renal tissue damage in diabetic nephropathy. (PMID 9044316). The rate of accumulation of glycoxidation products is accelerated in diabetes and age-adjusted concentrations of two advanced glycation end-products (AGE) in tissue proteins, N(6)-carboxymethyllysine and pentosidine, correlate with the severity of complication in diabetic patients. (PMID 9044306). Pentosidine is a carbohydrate-derived advanced glycation end products (AGEs) that is considerably elevated in uremic patients. Derived from ribose, a pentose, pentosidine forms fluorescent cross-links between the arginine and lysine residues in collagen. It is formed in a reaction of the amino acids with the Maillard reaction products of ribose. Although it is present only in trace concentrations among tissue proteins, it is useful for assessing cumulative damage to proteins-advanced glycation endproductsThis compound per se has no biological activities but is highly correlated to the levels of precursors of carbonyl compounds, and for this reason is considered a reliable surrogate marker for AGEs. The modification of proteins in uremia is not limited to AGEs, since advanced lipoxidation end products are also demonstrable in plasma proteins in uremia. The accumulation of these compounds does not seem to be dependent only on the decline of renal function. Carbonyl precursors of AGEs and advanced lipoxidation end products are markedly elevated in uremic patients. Preliminary cross-sectional studies in haemodialysis patients seem to indicate that the AGEs and carbonyl stress may be involved in the pathogenesis of alterations in left ventricular geometry and function in these patients. (PMID 11051031) D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003432 - Cross-Linking Reagents
4R-Hydroxy solifenacin
4R-Hydroxy solifenacin is a metabolite of solifenacin. Solifenacin (trade name Vesicare) is a urinary antispasmodic of the antimuscarinic class. It is used in the treatment of overactive bladder with or without urge incontinence. It is manufactured by Astellas and co-marketed by Astellas and GlaxoSmithKline. (Wikipedia)
3-(2-Propylpentanoyl)-5,5-diphenylhydantoin
9-Fluorocortisone
9-Fluoroprednisolone
Fluprednisolone
Ala Ala Ala Phe
Ala Ala Phe Ala
Ala Phe Ala Ala
Phe Ala Ala Ala
Phe Gly Gly Val
Phe Gly Val Gly
Phe Val Gly Gly
Gly Phe Gly Val
Gly Phe Val Gly
Gly Gly Phe Val
Gly Gly Val Phe
Gly Val Phe Gly
Gly Val Gly Phe
Val Phe Gly Gly
Val Gly Phe Gly
Val Gly Gly Phe
Pentosidine
An imidazopyridine having norleucine and ornithine residues attached via their side-chains at the 4- and 2-positions respectively. D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D003432 - Cross-Linking Reagents
(-)-DIISOPROPYL O,O-BIS(TRIMETHYLSILYL)-D-TARTRATE
tert-Butyl 2-((tert-Butyldimethylsilyloxy)methyl)furo[3,2-b]pyridin-6-ylcarbamate
12-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]dodecanoic acid
8-Benzyl-2-(4-methoxybenzyl)-2,8-diazaspiro[4.5]decane-1,3-dione
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclopentyl-N-(phenylmethyl)- (9CI)
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclopentyl-N-(4-methylphenyl)- (9CI)
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclopentyl-N-(3-methylphenyl)- (9CI)
Thiourea, N-[2-(1H-benzimidazol-2-yl)ethyl]-N-cyclohexyl-N-phenyl- (9CI)
Tixocortol
A - Alimentary tract and metabolism > A07 - Antidiarrheals, intestinal antiinflammatory/antiinfective agents > A07E - Intestinal antiinflammatory agents > A07EA - Corticosteroids acting locally R - Respiratory system > R01 - Nasal preparations > R01A - Decongestants and other nasal preparations for topical use > R01AD - Corticosteroids C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
12alpha-(Chloromethyl)-12-hydroxy-pregn-4-ene-3,20-dione
4-[5-(4-ethoxyphenyl)-3-isoxazolyl]-N-[(4-methylphenyl)methyl]butanamide
N-cycloheptyl-1-(4-methylphenyl)sulfonyl-4-piperidinecarboxamide
4-hydroxy-2-oxo-1-pentyl-N-(1-phenylethyl)-1,2-dihydroquinoline-3-carboxamide
[(2S,3R)-1-(cyclopentylmethyl)-6-ethylsulfonyl-3-phenyl-1,6-diazaspiro[3.3]heptan-2-yl]methanol
(1R,9R)-5-cyclohexyl-11-propylsulonyl-7,11-diazatricyclo[7.3.1.02,7]trideca-2,4-dien-6-one
3-Ethoxy-6-(1,5-dihydroxy-5-methyl-4-phenylthiohexyl)-2-cyclohexen-1-one
16-ethoxystrychnine
{"Ingredient_id": "HBIN001898","Ingredient_name": "16-ethoxystrychnine","Alias": "NA","Ingredient_formula": "C23H26N2O3","Ingredient_Smile": "CCOC12CC3C4C5CC(=O)N6C4C1(CCN2CC3=CCO5)C7=CC=CC=C76","Ingredient_weight": "378.5 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7416","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "200053","DrugBank_id": "NA"}
